Celltrion earmarks billions of dollars to build CDMO plant: chairman
Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...
Celltrion chairman announces venture into CDMO market
South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...
Celltrion scraps merger with Celltrion Pharm
South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&...
Costco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials
Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Biotech stocks, foreigners’ top pick in Korea amid panic selling
Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...
SIMPAC, Brazil's RIMA to set up ferrosilicon joint venture
SIMPAC Inc., a South Korean ferroalloy producer, said on Monday that it will establish a joint venture with Brazilian silicon alloy manufacturer RIM...
Celltrion's Zymfentra joins US insurance-covered drug lists
South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Celltrion’s new plant in Songdo poised for commercial production
South Korea’s largest biosimilar maker Celltrion Inc. said on Tuesday that its third plant in Sondgo, west of Seoul, is undergoing process val...
Celltrion's Remsima SC breaks 20% market share in Europe
South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed...
Samsung Electronics holds Latin America Tech Seminar
Samsung Electronics Co. announced on Thursday that it hosted the 2024 Latin America Tech Seminar in Sao Paulo, Brazil, on May 28 and 29.According to...
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
Korean construction machine makers set sights on India, Brazil, Mexico
South Korea’s leading construction machine makers are actively advancing into emerging markets such as India, Brazil, Mexico and Saudi Arabia,...
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
South Korea’s Osstem Implant Co., the world’s fourth-largest dental implant maker, is slated to acquire Brazilian peer Implacil De Borto...
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales
Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...
KAI inks $723 mn eVTOL aircraft parts deal with Brazil’s Eve
Korea Aerospace Industries Ltd. (KAI), the country’s sole military aircraft manufacturer, said it signed a 1 trillion won ($723 million) deal ...
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Hyundai Motor, Toyota compete to take upper hand in Brazil
South Korea’s top automaker Hyundai Motor Co. and Japan’s No. 1 carmaker Toyota Motor Corp. have been competing for decades to take the ...
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Hyundai to reignite Brazil’s mobility push with $1.1 billion investment
South Korea’s top automaker Hyundai Motor Co. said on Friday it will invest $1.1 billion in Brazil to reinvigorate the South American country&...
Celltrion to deliver three treatments to Peru
South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Celltrion, WuXi XDC to develop new antibody-drug conjugates
South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Celltrion revises up earnings goals to overtake Amgen
Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutical com...
